Is AOD-9604 Legal in Georgia? How Women Can Access It Safely

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide fragment. It corresponds to amino acids 176 to 191 of human growth hormone (hGH), with a tyrosine added at the N-terminus. The fragment was isolated because researchers believed this region of hGH drives fat metabolism without triggering the insulin resistance and cell-proliferation effects of full-length hGH.

The company Metabolic Pharmaceuticals tested it in clinical trials through the early 2000s. The most cited study, METAOD006, a Phase 2b randomized controlled trial, enrolled 300 overweight adults and found that 1 mg/day of oral AOD-9604 produced modest but statistically significant weight loss compared to placebo over 12 weeks. The peptide did not raise IGF-1 or fasting glucose, which was considered a safety advantage over full-length hGH.

Metabolic Pharmaceuticals ultimately did not pursue FDA approval for an obesity indication. The compound never completed Phase 3 trials for weight loss in the United States, leaving it without an approved drug status.

Why the Mechanism Matters for Women

Fat distribution in women is hormonally driven. Estrogen promotes subcutaneous fat storage in the hips, thighs, and breasts during reproductive years. At perimenopause, declining estrogen shifts fat toward the abdomen and visceral compartments, which raises cardiometabolic risk. This visceral shift is documented in the Study of Women's Health Across the Nation (SWAN), which tracked body composition in women across the menopausal transition.

AOD-9604's proposed mechanism targets lipolysis through beta-3 adrenergic receptors and inhibits lipogenesis. Whether this mechanism performs differently in an estrogen-replete versus estrogen-depleted environment has not been studied in any published clinical trial. That is a genuine data gap you deserve to know about before starting the peptide.

The Evidence Gap in Women

The METAOD006 trial included both men and women, but sex-disaggregated results were not published in the primary paper. No trial has examined AOD-9604 specifically in perimenopausal or postmenopausal women, in women with PCOS, or in women with hypothyroidism-related weight gain. Any claim about how AOD-9604 performs in these populations is extrapolated from mixed-sex data or animal models. This is standard in peptide research, but it is a limitation you should weigh.

Federal Legal Status: The FDA Framework You Need to Understand

AOD-9604 does not hold FDA approval as a drug product. That single fact drives everything about its legal status.

The 503A and 503B Compounding Pathway

Under the Federal Food, Drug, and Cosmetic Act sections 503A and 503B, licensed compounding pharmacies may prepare drugs that are not commercially available, provided the ingredients meet specific criteria. For a bulk drug substance (a raw active ingredient not derived from an approved finished drug) to be used in compounding, it must appear on the FDA's 503A or 503B bulk drug substance lists, or be under evaluation for those lists.

AOD-9604 has been subject to FDA scrutiny under this framework. The FDA has at various times placed peptides, including AOD-9604, on lists indicating they are under evaluation or are not eligible for use in compounding. The FDA's current bulk drug substance list and nomination tracking is publicly available and changes periodically. As of the date of this article, AOD-9604's eligibility for compounding is in a contested gray zone at the federal level.

That gray zone is not hypothetical. In 2023 and 2024, the FDA sent warning letters to compounders selling peptides, including BPC-157 and other growth hormone fragments, for marketing them as bulk drug substances without adequate regulatory standing. AOD-9604 has not been exempted from this scrutiny.

The practical consequence: some 503A compounding pharmacies in Georgia and nationally continue to prepare AOD-9604 with a valid prescription, while others have stopped pending clearer federal guidance. The legal exposure, if any, falls primarily on the compounder and the prescriber, not on the patient who receives a legitimately prescribed compound. Still, you should know the regulatory environment is unsettled.

Research Use vs. Clinical Use

A separate category exists: research chemicals sold "not for human use." You will see AOD-9604 sold online from peptide research vendors with that label. Purchasing these products for self-injection is outside any legal medical framework. These products are not subject to pharmaceutical-grade manufacturing standards, sterility testing, or potency verification. For women, the risks include injection-site infections, unknown hormonal contaminants, and no prescriber oversight if something goes wrong. This article does not recommend that path.

Georgia State Law: What the State Actually Regulates

Georgia does not have a statute that specifically names AOD-9604 or any comparable peptide as a controlled or banned substance under state law. Georgia's controlled substances schedules, governed by O.C.G.A. Title 16, Chapter 13, follow the federal Controlled Substances Act schedules closely and do not list AOD-9604.

The Georgia State Board of Pharmacy

The Georgia State Board of Pharmacy regulates compounding pharmacies operating in the state. Georgia-licensed compounders must comply with both state board rules and federal USP standards (USP 797 for sterile preparations, which applies to injectable peptides). A Georgia 503A pharmacy that compounds AOD-9604 must do so in response to a valid patient-specific prescription from a licensed Georgia practitioner, not for office-stock or general sale.

The Georgia Medical Practice Act

Under the Georgia Medical Practice Act, a licensed physician, advanced practice registered nurse with prescriptive authority, or other authorized prescriber may prescribe a compounded preparation if it is medically appropriate for an individual patient. There is no Georgia rule that prohibits prescribing AOD-9604 as a compounded agent. The prescriber's professional and legal risk arises primarily from federal, not state, regulation.

What This Means Practically

Georgia residents can legally receive AOD-9604 through this pathway:

1. A licensed Georgia provider conducts a clinical evaluation and determines the compound is appropriate for your specific situation.
2. The provider writes a patient-specific prescription.
3. A Georgia-licensed or out-of-state 503A compounding pharmacy (that ships legally to Georgia) fills the prescription using pharmaceutical-grade bulk ingredients.
4. You self-administer the subcutaneous injection under provider supervision.

No step in that chain is prohibited under Georgia state law. The federal-level ambiguity over bulk ingredient eligibility is the limiting factor, not a Georgia statute.

How to Get AOD-9604 in Georgia: A Step-by-Step Guide

Step 1: Find a Knowledgeable Provider

Not every primary care physician or gynecologist is familiar with compounded peptides. You are more likely to find a prescriber comfortable with this area through:

• Functional medicine or integrative medicine practices in Georgia
• Obesity medicine-certified physicians (board certification through the American Board of Obesity Medicine)
• Women's health telehealth platforms that serve Georgia residents

Ask directly whether the practice has experience prescribing compounded peptides and works with a specific 503A pharmacy. A provider who cannot name the pharmacy they use is a red flag.

Step 2: Expect a Real Clinical Evaluation

A legitimate prescriber will review your weight history, metabolic labs (fasting glucose, HbA1c, fasting insulin, lipid panel, thyroid function), and any comorbidities. For women, this should include a menstrual history, current contraceptive method, and whether you are perimenopausal or postmenopausal, because these factors affect both your metabolic baseline and the risk discussion.

If a provider offers to prescribe AOD-9604 after a five-minute online questionnaire with no labs, that is not adequate care.

Step 3: Verify the Pharmacy

Ask whether the compounding pharmacy is PCAB-accredited (Pharmacy Compounding Accreditation Board). PCAB accreditation means the pharmacy has undergone independent quality inspection. Request the certificate of analysis (COA) for the specific batch of AOD-9604 you receive, confirming purity and potency.

Step 4: Understand What You Are Paying For

AOD-9604 is not covered by commercial insurance or Medicare in any indication. Expect to pay $150 to $400 per month depending on dose and pharmacy. Some telehealth platforms bundle provider visits into a monthly subscription; others charge separately. Get an itemized cost breakdown before committing.

AOD-9604 Across Women's Life Stages

This framework for thinking about AOD-9604 by life stage does not appear in any existing clinical guideline. It is offered here as a clinical-reasoning scaffold, not as evidence-based guidance, because no trial has addressed these populations specifically.

Reproductive Years (Ages Approximately 18 to 40)

Women with obesity or PCOS-related weight resistance are among those most likely to seek peptide-based fat loss tools. AOD-9604's proposed mechanism (lipolysis via beta-3 adrenergic pathways) is theoretically relevant to the androgen-driven, insulin-resistant adipose pattern seen in PCOS. However, no published study has tested AOD-9604 in women with PCOS. Until such data exist, any benefit is speculative.

Reliable contraception is mandatory during AOD-9604 use (see the Pregnancy and Lactation section below). Women using combined hormonal contraceptives should inform their prescriber, as estrogen-containing pills affect lipid metabolism and body composition in ways that could interact with a lipolytic agent, though no interaction data exist for this specific peptide.

Trying to Conceive

Stop AOD-9604 before attempting conception. There are no safety data in humans attempting pregnancy. Animal reproductive toxicology data for this compound are limited, and no risk threshold has been established.

Perimenopause (Approximately Ages 45 to 55, Variable)

The visceral fat shift of perimenopause is one of the most clinically significant body composition changes women face. Estrogen loss accelerates visceral adiposity and raises cardiovascular risk, independent of total body weight. Perimenopausal women may be highly motivated to address this shift.

AOD-9604 has not been studied in this population. If you are perimenopausal and considering AOD-9604, your prescriber should first evaluate whether menopausal hormone therapy (MHT) is appropriate, since MHT has documented evidence for attenuating the menopause-related fat redistribution and carries a much better evidence base than AOD-9604.

Post-Menopause

Post-menopausal women face the same data gap. The theoretical rationale for lipolysis support persists, but no trial data exist. Post-menopausal women on MHT should disclose all peptide use to their prescriber, as no drug-interaction studies exist.

Postpartum and Lactation

AOD-9604 should not be used postpartum while breastfeeding. See the dedicated section below.

Pregnancy, Lactation, and Contraception: What You Must Know

Pregnancy: Do not use AOD-9604 during pregnancy.

There are no human safety data for AOD-9604 in pregnancy. The compound has not been assigned an FDA pregnancy category because it was never approved. Animal data are limited to early-phase pharmacology studies and do not establish a safe exposure level. The precautionary recommendation from any evidence-based standpoint is to avoid use entirely during pregnancy.

The FDA's general guidance on unapproved compounds in pregnancy is to weigh unknown risk against benefit, a calculation that cannot be made responsibly for AOD-9604 given absent human gestational data.

If you discover you are pregnant while using AOD-9604, stop the peptide immediately and contact your obstetric provider.

Lactation: Avoid during breastfeeding.

No lactation transfer data exist for AOD-9604. The molecular weight of the peptide (approximately 1,817 daltons) means it is likely to have low oral bioavailability in a nursing infant even if it does transfer into milk. However, "likely low" is not "absent," and no study has measured milk concentration or infant exposure. The conservative and appropriate recommendation is to stop AOD-9604 while breastfeeding and discuss resumption with your provider after weaning.

Contraception: Required.

Because embryonic safety data are absent, anyone of reproductive potential using AOD-9604 should use reliable contraception. This means a method with a typical-use failure rate below 1 percent per year: an IUD (hormonal or copper), subdermal implant, or consistent combined hormonal method. Barrier methods alone are not adequate given the absent fetal safety data.

Who This May Be Right For, and Who Should Avoid It

Potentially Appropriate (with provider oversight)

• Non-pregnant, non-breastfeeding women with excess adiposity who have plateaued on first-line interventions (dietary change, exercise, and where appropriate, FDA-approved medications such as GLP-1 receptor agonists)
• Women who cannot tolerate GLP-1 agents due to severe gastrointestinal side effects and are seeking alternative options under medical supervision
• Post-menopausal women with visceral adiposity who have already addressed MHT eligibility with their provider

Not Appropriate

• Pregnant women (any trimester)
• Breastfeeding women
• Women trying to conceive
• Women with active malignancy or a personal history of growth-related tumors (theoretical concern given the growth hormone fragment origin, though AOD-9604 does not appear to raise IGF-1 based on available trial data)
• Women who have not first tried evidence-based weight management: caloric deficit, physical activity, and where indicated, FDA-approved pharmacotherapy such as semaglutide (approved for chronic weight management at 2.4 mg weekly) or tirzepatide

Comparing AOD-9604 to FDA-Approved Weight Loss Options for Women

AOD-9604 is not a replacement for approved medications. The comparison matters because women are often presented with peptides as equivalent or superior alternatives without data to support that framing.

Semaglutide 2.4 mg weekly (Wegovy) produced a mean body weight reduction of 14.9% over 68 weeks in the STEP 1 trial (n=1,961, approximately 75% women). That is a large, Phase 3, FDA-reviewed dataset. AOD-9604's best result, from METAOD006, was approximately 2.5 kg over 12 weeks in a mixed-sex sample. These are not comparable evidence bases.

If you are a candidate for a GLP-1 receptor agonist, that conversation should happen before a peptide discussion.

Side Effects and Monitoring for Women

The METAOD006 trial reported AOD-9604 as well-tolerated, with injection-site reactions (redness, mild pain) being the most common adverse event. No serious adverse events were attributed to the drug in that trial. However:

• The trial enrolled a maximum of 300 participants, which is insufficient to detect rare adverse events.
• Long-term safety data beyond 24 weeks do not exist for any population.
• Women-specific hormonal effects (on the hypothalamic-pituitary-gonadal axis, menstrual cycle regularity, or thyroid function) have not been studied.

Your prescriber should monitor fasting glucose, lipids, and thyroid function at baseline and at three to six months. Report any menstrual irregularity that begins after starting the peptide, as this may indicate an unrelated condition that warrants evaluation.